| Literature DB >> 24723849 |
Henry H Jerng1, Paul J Pfaffinger1.
Abstract
Auxiliary subunits are non-conducting, modulatory components of the multi-protein ion channel complexes that underlie normal neuronal signaling. They interact with the pore-forming α-subunits to modulate surface distribution, ion conductance, and channel gating properties. For the somatodendritic subthreshold A-type potassium (ISA) channel based on Kv4 α-subunits, two types of auxiliary subunits have been extensively studied: Kv channel-interacting proteins (KChIPs) and dipeptidyl peptidase-like proteins (DPLPs). KChIPs are cytoplasmic calcium-binding proteins that interact with intracellular portions of the Kv4 subunits, whereas DPLPs are type II transmembrane proteins that associate with the Kv4 channel core. Both KChIPs and DPLPs genes contain multiple start sites that are used by various neuronal populations to drive the differential expression of functionally distinct N-terminal variants. In turn, these N-terminal variants generate tremendous functional diversity across the nervous system. Here, we focus our review on (1) the molecular mechanism underlying the unique properties of different N-terminal variants, (2) the shaping of native ISA properties by the concerted actions of KChIPs and DPLP variants, and (3) the surprising ways that KChIPs and DPLPs coordinate the activity of multiple channels to fine-tune neuronal excitability. Unlocking the unique contributions of different auxiliary subunit N-terminal variants may provide an important opportunity to develop novel targeted therapeutics to treat numerous neurological disorders.Entities:
Keywords: Kv channel-interacting protein; N-terminal variant; auxiliary subunit; dipeptidyl peptidase-like protein; excitability; modulatory mechanism; potassium channel; somatodendritic A-type current
Year: 2014 PMID: 24723849 PMCID: PMC3973911 DOI: 10.3389/fncel.2014.00082
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Validation of auxiliary subunits and accessory proteins.
| Proteins | Kv4.2-IP PAF | Kv4 CoIP | Δ Ipeak | Δ Functional properties |
|---|---|---|---|---|
| KChIP1 | – | Brain | ↑ 7.5-fold | Slowed inactivation; rightward shift in SSI; accelerated recovery; accelerated closing ( |
| KChIP2 | 1.7 | Brain | ↑ 5.5-fold | |
| KChIP3 | 1.4 | Brain | ↑ 5.8-fold | |
| KChIP4 | 5.6 | Brain | ↑ 2- to 3-fold | |
| DPP6 | 5.3 | Brain | ↑ 4- to 18-fold | Accelerated activation and inactivation; leftward shifts in SSI and G-V relationship; accelerated recovery; accelerated channel closing ( |
| DPP10 | 2.0 | Brain | ↑ 5.9-fold | |
| Kvβ1 | 0.7 | Brain | ↑ 0.2- to 3-fold | Moderate acceleration of inactivation; moderate to no effect on SSI; no effect on recovery; Kv1 preference ( |
| Navβ1 | 0.8 | Brain Heart | ↑ 0.3- to 2-fold | Inconsistent effects reported ( |
| MiRP1 | – | Variable | Inconsistent effects reported ( | |
| KChAP | – | Heart | ↑ 0.8-fold | None ( |
| NCS-1 | – | Heart | ↑ 0.5-fold | Inconsistent effects reported ( |
| PSD-95 | – | ↑ 2-fold | None ( | |
| Filamin | – | Brain | ↑ 2.5-fold | None ( |
| Kinesin isoform Kif17 | – | Brain | ND | ND ( |
Genetic association between I subunits and disease/disorders.
| Subunit | Phenotype | Subject | Conclusion and analysis method | Reference |
|---|---|---|---|---|
| Kv4.2 | Temporal lobe epilepsy | Human-Japanese | Yes: electrophysiology | |
| KChIP | Ventricular tachycardia | Mouse | Yes: KChIP2 knockout | |
| Pain | Mouse | Yes: KChIP3 knockout | ||
| DPP6 | Amyotrophic lateral sclerosis | Human-multi-ethnic | Inconsistent: GWAS analysis SNP analysis CNV association | |
| Progressive multiple sclerosis | Human-Italian | Yes: SNP analysis | ||
| Tardive dyskinesia schizophrenia | Human-Japanese | Yes: GWAS analysis | ||
| Autism spectrum disorder | Human-multi-ethnic | Yes: ID mutations CNV association | ||
| Microcephaly | Human-Chinese | Yes: CNV association | ||
| DPP10 | Asthma | Human-multi-ethnic | Yes: SNP association GWAS analysis Positional cloning | |
| Autism spectrum disorder | Human-mixed | Yes: CNV analysis | ||
| Bipolar disorder schizophrenia | Human-Norwegian | Yes: GWAS analysis |